Navigation Links
Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
Date:8/3/2010

THE WOODLANDS, Texas, Aug. 3 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will release its second quarter 2010 financial results on Monday, August 9, 2010 before the financial markets open.  Lexicon management will hold a conference call to discuss its clinical development progress and financial results for the quarter at 11:00 a.m. Eastern Time that same day.

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 92435005.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the webcast will be available on the website through August 16, 2010.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
2. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
3. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
4. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
5. Lexicon to Present at BIO International Convention
6. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
7. Lexicon Announces Proposed $95 Million Common Stock Offering
8. Lexicon to Report Fourth Quarter and Year End 2009 Financial Results on February 23, 2010
9. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
10. Lexicon to Host Conference Call and Webcast to Review Top-Line Phase 2 Results From Diabetes Trial
11. Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... company focused on the development of oral drug delivery systems, ... Securities Authority to dual-list its common stock on the Tel ... on the TASE on July 12, 2017 under the ticker ... it is expected that Oramed will be included in the ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
(Date:6/30/2017)... ROCKVILLE, Md. , June 30, 2017 ... that since the start of May, at least ten ... financings include private investments, public offerings and a loan ... $3.3 million to almost $80 million.  Kalorama Information provides ... customers of its Diagnostics Knowledge Center. ...
Breaking Medicine Technology:
(Date:7/21/2017)... CA (PRWEB) , ... July 21, 2017 , ... West ... “Tu” Tuantu Doan Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West ... 27 years of experience in dermatology, skin cancer , and more. She graduated ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is a set of transitions ... timeline. This effect isolates horizontal and vertical lines of pixels and sorts their pixels ... or flipping animation and can be changed using a drop-down menu. Create amazing and ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... firm headquartered in Houston, is pleased to announce their expansion to the Midwest ... housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John Peck ...
(Date:7/20/2017)... ... July 20, 2017 , ... Doctors on Liens, the leading network of medical ... , directed by Dr. Russell Horine, DC to their exclusive list of medical professionals. ... Russell Horine serving as the clinic director and his son Dr. Lee Horine and ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Dermatology Clinic announced ... Dunbar received his BS in Biology from LSU, graduating summa cum laude. He attended ... President. After his residency in St. Louis, Dr. Dunbar moved to New York to ...
Breaking Medicine News(10 mins):